## Hormone Receptor Status and Breast Cancer Prognosis **Key Point:** Triple-negative breast cancer (ER−/PR−/HER2−) has the worst prognosis among all molecular subtypes due to lack of targeted therapy options and inherently aggressive biology [cite:Robbins 10e Ch 23]. ### Molecular Subtypes and Prognosis | Receptor Status | Molecular Subtype | Prognosis | Treatment Options | | --- | --- | --- | --- | | ER+/PR+/HER2− | Luminal A | Best | Endocrine therapy | | ER+/PR±/HER2+ | Luminal B | Good | Endocrine + HER2-targeted | | ER−/PR−/HER2+ | HER2-enriched | Intermediate | HER2-targeted therapy | | ER−/PR−/HER2− | Triple-negative | Worst | Chemotherapy only | **High-Yield:** Triple-negative breast cancers (TNBC) are: - More common in younger women and African Americans - Associated with BRCA1 mutations - Highly aggressive with rapid progression - Limited to chemotherapy as systemic treatment (no endocrine or HER2-targeted options) - 5-year survival significantly lower than hormone receptor-positive cancers **Mnemonic:** **TNBC = Tough, No Targeted therapy, Bad prognosis** — Remember that the absence of targetable receptors (ER, PR, HER2) means chemotherapy is the only systemic option, and these tumors tend to be more chemoresistant. **Clinical Pearl:** Recent advances in immunotherapy (checkpoint inhibitors) and PARP inhibitors (in BRCA-mutated TNBC) are improving outcomes, but TNBC remains the most challenging subtype to treat.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.